#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Porphyria non-acute Adenomatous polyposis coli Glomerulonephritis membranoproliferative Hereditary motor and sensory neuropathy Conjunctivitis allergic Fibrodysplasia ossificans progressiva Niemann-Pick disease Lennox-Gastaut syndrome Warm autoimmune haemolytic anaemia Neuromyelitis optica spectrum disorder Restless legs syndrome Cushing's syndrome Carcinoid syndrome Adenoid cystic carcinoma Non-renal cell carcinoma of kidney More trials…

    Learn about Rare Diseases

    Atypical haemolytic uraemic syndrome – Treatment Angelman’s syndrome – Basic Information Mantle cell lymphoma stage II Alexander disease – Trials in Disease Amyotrophic lateral sclerosis – Trials in Disease Mucopolysaccharidosis I – Trials in Disease IgA nephropathy – Treatment Piriformis syndrome – Basic Information Lennox-Gastaut syndrome – Treatment Waldenstrom’s macroglobulinaemia refractory – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gallium Citrate Ga-68 Magnesium Hydroxide Falbikitug IMELASOMERAN GSKVX000000034796 Padeliporfin Ucp4 Glimepiride Imatinib Folinic Acid Fludarabine Vancomycin Hydrochloride Farletuzumab Ecteribulin Bepirovirsen Crizanlizumab Febuxostat Brexucabtagene Autoleucel Lactose Monohydrate Xenon (129Xe) [68GA]GA-NOTA-AE105 More therapies…

    Learn about Your Condition

    Gastric cancer Tuberous sclerosis complex Juvenile absence epilepsy Neuropathy peripheral Pseudoxanthoma elasticum Mantle cell lymphoma stage II Postprandial hypoglycaemia Respiratory tract infection Inclusion body myositis Primary myelofibrosis Post-traumatic headache Seasonal allergy Hypersensitivity IgA nephropathy Bone metabolism disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Università degli studi Gabriele D’Annunzio Chieti-Pescara…

Università degli studi Gabriele D’Annunzio Chieti-Pescara Centro di Studi e tecnologie avanzate

Vic Dvs Vhtuvlg 3mh Caxtisq 6ulntr Iuoxm

Want to learn more about this study or check if you can participate? Contact us.

  • Safety and dose‑finding study of trazodone hydrochloride and psilocybin in patients with treatment‑resistant depression

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • TRAZODONE HYDROCHLORIDE
    • Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
    Italy

  • A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

    Recruiting

    3 1
    Investigated Diseases:
    • Primary progressive multiple sclerosis
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • A study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer’s disease

    Recruiting

    4 1
    Investigated Diseases:
    • Agitation
    • Dementia Alzheimer’s type
    Czechia Germany Italy Poland Slovakia Spain

  • Efficacy and safety of gadopiclenol versus gadoteric acid‑enhanced MRA in adult patients with suspected vascular disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Gadoteric Acid
    Czechia France Germany Hungary Italy Poland +1

  • A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

    Recruiting

    2 1
    Investigated Drugs:
    • SAR445399
    Belgium France Germany Hungary Italy Spain +1

  • A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

    Recruiting

    3 1
    Investigated Drugs:
    • Remibrutinib
    Austria Belgium Bulgaria Croatia Czechia Denmark +19

  • Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Ustekinumab
    • Deucravacitinib
    Belgium Bulgaria Czechia Denmark France Germany +6

  • A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • RO7268489
    • Ocrelizumab
    France Germany Hungary Italy Poland Portugal +1

  • Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

    Recruiting

    3 1 1
    Investigated Drugs:
    • VORMATRIGINE
    • Prax-628
    Germany Italy Poland Spain
1 2 3 … 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!